News

Tech Startups Apply for Fall RAMP Cohort

RAMP is accepting applications are for their fall cohort to begin in September 2021.

RAMP is looking for technology startups with scalability, and coachable entrepreneurs who have a desire to do the work.

RAMP will select up to five companies for the 12-week cohort that provides:

• Expert 1:1 mentoring with the region’s top entrepreneurs and executives
• Free office space with high-speed internet in downtown Roanoke in Virginia’s Blue Ridge
• Access to venture capital
• $20,000 in equity-free funding

 

Application Close Date: August 15 Cohort

Start Date: September 13

DEMO DAY (tentative): December 9

Visit here to apply.

Recent News

02/24/2026

Jeeva Clinical Trials Calls on Global Life Sciences Leaders to Modernize Infrastructure for AI-Driven Drug Development

Jeeva Clinical Trials today amplified its call to action for the global pharmaceutical and clinical research ecosystem: Artificial Intelligence will not transform drug development unless organizations modernize the IT infrastructure beneath it. The message — first articulated in a recent thought leadership article by Founder and CEO Harsha K. Rajasimha — has gained strong traction

02/24/2026

Liquet™ Medical Receives Second FDA 510(k) Clearance for Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new configuration of the Versus™ Catheter. The latest clearance expands the company’s proprietary platform and opens access to a broader

02/17/2026

Serpin Pharma, Inc. Announces Approval to Initiate EASE‑AKI Phase II Clinical Trial in Germany

Serpin Pharma, Inc., a clinical‑stage biopharmaceutical company developing first‑in‑class LRP1‑agonist therapeutics, today announced that its Phase II clinical trial, EASE-AKI, has received unconditional approval to begin enrolling patients in Germany. The study will evaluate SP16, a powerful yet well-tolerated anti-inflammatory peptide, designed to protect the kidneys of patients with chronic kidney disease who are undergoing